Sanofi plans to make insulin more affordable and accessible for all patients next year.
The company has taken action to fix insulin prices at $35 per month beginning next year, expanding an existing program.
“Our announcement builds on an idea first championed by President Trump to lower costs for American patients at the pharmacy counter. At Sanofi, we share his objective and believe that no one should struggle to afford their insulin and we are proud to take this next step as we play our part to keep America healthy,” said Adam Gluck, Head of US Corporate Affairs, Sanofi.
Five things to know:
- The pharmaceutical giant launched the Valyou Savings Program in 2022 lowering the cost of 30-day packages of insulin from $99 to $35 for diabetic patients without insurance.
- The company plans to expand the program to all individuals with a valid prescription Jan. 1, 2026, including those with commercial insurance and Medicare beneficiaries.
- Sanofi is expanding the program to most pharmacies in the U.S., including independent and rural pharmacies.
- Individuals with a valid prescription will be able to purchase any combination, type and quantity of Sanofi insulin for the $35 fixed monthly price.
- There are around 38.4 million Americans, 11.6% of the population, diagnosed with diabetes, according to the CDC.
“By expanding our Insulins Valyou Savings Program, we’re taking concrete action to address a critical healthcare issue for millions of Americans living with diabetes,” said Mr. Gluck. “We will continue to work with policymakers and stakeholders across the healthcare system on additional sustainable, long-term solutions to improve access to medicines.”
The Sept. 26 announcement came two days after a Paris court ordered Sanofi to pay $177.1 million to France’s national health insurance fund for “anti-competitive practices” for its anti-clotting drug, according to Reuters, and one day after committing $625 million to Sanofi Ventures. The fund was launched to accelerate biotech and digital health investment.
